New drug combo aims to reboot immune system against tough head & neck cancers
NCT ID NCT04150900
Summary
This study is testing if adding an experimental drug called bavituximab to an approved immunotherapy (pembrolizumab) can help control advanced head and neck cancer that has started growing again after prior immunotherapy. It is for adults whose cancer has spread or returned and worsened despite previous treatments. The goal is to see if the combination can better engage the body's immune system to fight the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Maryland Medical Center
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.